key: cord-0275553-7w4c9j80
authors: Morimoto, S.; Takahashi, S.; Ito, D.; Date, Y.; Okada, K.; Muh Chyi, C.; Nishiyama, A.; Suzuki, N.; Fujimori, K.; Takao, M.; Hirai, M.; Yasuaki, K.; Suematsu, M.; Jinzaki, M.; Aoki, M.; Fujiki, Y.; Sato, Y.; Nakahara, J.; Okano, H.
title: Ropinirole hydrochloride for amyotrophic lateral sclerosis: A single-center, randomized feasibility, double-blind, placebo-controlled trial
date: 2021-12-07
journal: nan
DOI: 10.1101/2021.12.05.21267266
sha: d53bb62b829ecd2295fd8f98721ffd206ca538ab
doc_id: 275553
cord_uid: 7w4c9j80

Background We previously used an induced pluripotent stem cell-based drug repurposing approach to demonstrate that ropinirole hydrochloride (ropinirole) attenuated amyotrophic lateral sclerosis (ALS)-specific pathological phenotypes. Here, we assessed the safety and efficacy of ropinirole in ALS patients. Methods We conducted a phase 1/2a trial in ALS. 20 participants were randomly assigned to receive ropinirole or placebo for 24 weeks in the double-blind period. Upon completion, participants could choose to participate in the following 24-week open-label active extension period. Primary outcomes were safety and tolerability. Secondary outcomes were a change in the ALS Functional Rating Scale-Revised score, composite functional endpoint, combined assessment of function and survival, event-free survival, and time to [≤]50% forced vital capacity. This study is registered with the UMIN Clinical Trials Registry, UMIN000034954. Findings Twenty participants received ropinirole (n=13) or placebo (n=7). Overall, the incidence of adverse events was similar in both groups, most of which had been reported previously. Notably, gastrointestinal disorders (mainly, temporary mild nausea and diarrhoea) had a high incidence of 76{middle dot}9% in the ropinirole group (14{middle dot}3% in the placebo group). Regarding the evidence of efficacy, participants in the ropinirole group had significantly higher combined assessment of function and survival scores (p=0{middle dot}023) and lived an additional 195 days without disease progression events compared with the placebo group (log-rank test, 95% confidence interval, 4{middle dot}3-37{middle dot}4) in the entire period (secondary outcomes). Interpretation Ropinirole was safe and tolerable for patients with ALS and this trial provided small-scale evidence of its clinical efficacy. Funding This study was funded by The Japan Agency for Medical Research and Development and K Pharma Inc.

1 Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease. The median survival time of 2 patients with ALS is approximately 2 years, and muscle weakness eventually causes respiratory 3 failure and death. 1 Currently, there are two Food and Drug Administration-approved drugs for 4 the treatment of ALS: riluzole and edaravone. Riluzole extends survival by 2-3 months with no 5 reported benefits to muscle strength, whereas edaravone improves short-term functional 6 outcomes but has no statistically significant effect on survival. 2 Therefore, the need for effective 7 ALS therapies remains unmet. 8

Drug development for diseases of the nervous system has the second-lowest success rate at the 9 pivotal phase compared with other therapeutic areas. 3 In particular, neurodegenerative diseases 10 are heterogeneous and the majority of them is sporadic, limiting the translational potential of 11 preclinical animal models. By exploiting induced pluripotent stem cell (iPSC)-derived motor 12 neurons (MNs) generated from patients with ALS, we sought to enable large-scale drug 13 screening and overcome the limitations of preclinical animal models for the development of 14 drugs to treat highly heterogeneous neurodegenerative diseases. Ropinirole is a commonly used drug for Parkinson's disease (PD) that can permeate the blood-25 brain barrier. Of note, our in vitro model suggested that ropinirole was more potent than other 26 ALS drugs and investigational drugs, including riluzole, edaravone, and ceftriaxone. 5 27

Interestingly, other dopamine D2 receptor agonists such as bromocriptine and pramipexole 28 (dexpramipexole), have been reported to be candidates for therapeutics for ALS, 6,7 but these 1 drugs failed to show efficacy in clinical trials had. 8-11 2 Based on the safety profile of ropinirole for PD, we hypothesized that ropinirole would be well 3 tolerated in patients with ALS. Here, we present the results of the Ropinirole Hydrochloride 4

Remedy for Amyotrophic Lateral Sclerosis (ROPALS) single-centre, randomized, placebo-5 controlled trial, which evaluated the safety and efficacy of ropinirole with the following 6 parameters: ALS Functional Rating Scale-Revised (ALSFRS-R) score, 12 The ROPALS trial was an investigator-led, double-blind, placebo-controlled, randomized phase 12 1/2a trial conducted at a single site (Keio University Hospital) in Japan beginning in Dec 2018 13 (figure S1). This trial was approved by the Institutional Review Board of Keio University 14 Hospital (No. D18-01). Participating investigators are listed in Section S1. Participants were 15 followed up for 64 weeks, which comprised a run-in period of 12 weeks followed by a 48-week 16 intervention period and a 4-week follow-up period (figure S1). 17 We conducted this trial in accordance with the Good Clinical Practice guidelines of the 18 International Council for Harmonisation, and the trial protocol was approved by our institutional 19 review board. The trial protocol has been published, 15 This trial included patients with ALS who satisfied all the inclusion criteria (patients with a 27 change in the ALSFRS-R score within the range of −2 to −5 points during the 12-week run-in 28 period at official registration) and did not meet any of the exclusion criteria (patients with a 29 family history or prior diagnosis of superoxide dismutase (SOD)-1 mutation). Furthermore, 30 before the start of the first dose of study treatment; at weeks 5, 9, 13, 17, 21, 24, 27, 31, 35, 39,  1 43, 47, and 50 after the start of study treatment; during the follow-up period; and at the time of 2 discontinuation. The amount of physical activity (METs: metabolic equivalents) was measured 3 every 10 seconds by Active style Pro HJA-750C with a high precision 3D accelerometer 4 (OMRON, Kyoto, Japan) and evaluated as the 4-week mean value. In addition, cerebrospinal 5 fluid (CSF) tests were performed using lumbar puncture before the start of the first dose of the 6 study treatment, before study drug administration at weeks 24 and 50 after the start of study 7 treatment, and at the time of discontinuation. A detailed schedule of the assessments is provided 8 in the protocol. Data were collected with an electronic case-report form using Viedoc (Viedoc 9 Japan K.K., Tokyo, Japan). 10

In the randomized study, the primary outcomes were AEs, laboratory test values, and the 12 proportion of discontinued subjects during the double-blind period. AEs were graded for severity 13 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5·0 and 14 relation to the study drug. The secondary outcomes for the feasibility trial objective included the 15 ratio of the change in the ALSFRS-R score every 4 weeks between pre-and posttreatment 16 assessments, change in the ALSFRS-R score, 12 combined assessment of function and survival 17 (CAFS) scores, 13 amount of physical activity, 14,18 composite endpoint as a sum of the Z-18 transformed scores of items (full items are provided in the protocol), 19 time to death or a 19 specified state of disease progression, and time to %FVC of ≤ 50%. Exploratory outcomes are 20 provided in the protocol. 21

The probability of detecting an AE with a true incidence rate of 10% was 80% with 15 subjects 23 in the treatment group. Additionally, five subjects were randomly assigned to the placebo group 24 to collect efficacy and safety data and eliminate bias. 25

Statistical analyses and reporting of this trial were conducted in accordance with the CONSORT 26 statement guidelines, with the primary analyses based on the intention-to-treat principle. For 27 primary safety analysis, the proportion of AEs was estimated in each treatment group, and the 28 exact 95% confidence interval (CI) was calculated by the binomial distribution. 29

The secondary outcomes for efficacy were analysed using an analysis-of-covariance (ANCOVA) 30 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. model with fixed-effect terms for the study group and the corresponding baseline value as a  1 covariate. The change-from-baseline means are the least-squares means from the ANCOVA 2 model during the 24-week treatment period. For the sensitivity analysis, mean changes from 3 baseline were analysed using a restricted maximum likelihood (REML)-based repeated measures 4 approach in combination with the Newton Raphson algorithm. The mixed model for repeated 5 measures (MMRM) analyses included the fixed, categorical effects of treatment, visit, and 6 treatment by visit interaction. A common unstructured covariance structure was used for 7 modelling within the patient error. If this analysis failed to converge, the following structures 8 were tested until model convergence was achieved: Toeplitz, autoregressive, or compound-9 symmetry structures. The Kenward-Roger approximation was used to estimate the denominator 10 degrees of freedom. The calculation of risk difference and 95% CI according to the Newcombe-11

Wilson method was added to the efficacy endpoints. No adjustments were made for the multiple 12 testing of secondary outcomes because of the exploratory nature of the study. Missing values in 13 outcome variables were not imputed because mixed models can handle missing data by 14 maximum likelihood. 15 16 For time to event, the Kaplan-Meier method was applied to assess overall survival, and 17 competing risk analyses using the Cox model for time to death or a specified state of disease 18 progression and the Fine and Grey model for time to %FVC of ≤ 50% were performed to assess 19 disease progression times. Cumulative incidence curves are presented for each treatment group. 20

All comparisons were planned, and all p values are two-sided. A p value < 0·05 was considered 21 statistically significant. All statistical analyses were performed using SAS software version 9·4 22

(SAS Institute Inc., Cary, NC, USA) and described in the statistical analysis plan, which was 23 fixed prior to database locking. The trial was reported to the Japanese Pharmaceuticals and The role of GSK was in providing ropinirole extended-release tablets and placebo and that of K 29

Pharma was in funding. 30 31 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; This was a small-scale phase 1/2a randomized control trial, and two more subjects were allocated 9 to the placebo group than planned; therefore, the number of subjects in the placebo group was 10 seven with an allocation ratio of 2:1. According to Kang et al, at the initial stages of a clinical 11 study or for trials with small sample sizes, using simple randomization can cause an extreme 12 imbalance among the treatment groups by random chance alone. 20 13 Table 1 During the double-blind period, one death occurred in the placebo group (idiopathic ischaemic 24 heart disease on day 157), which was attributed to disease progression by the investigators. No 25 participant discontinued treatment due to adverse experiences in either treatment group. In total, 26 92·3% (12/13) and 85·7% (6/7) of participants experienced at least one AE in the ropinirole 27 group and the placebo group, respectively. AEs that occurred in ≥10% of participants in both 28 treatment groups included gastrointestinal disorders (14·3% for placebo and 76·9% for 1 ropinirole) and infection and infestations (28·6% for placebo and 23·1% for ropinirole). 2

Ropinirole-related AEs occurring in ≥20% of participants included constipation (61·5%), nausea 3 (38·5%), somnolence (30·8%), and headache (23·1%). No statistically significant abnormalities 4 were detected for conventional clinical laboratory measurements or CSF tests. 5

During the open-label active extension period, at least one AE occurred in 91·7% of participants 6 in the ropinirole-ropinirole (RR) treatment group and 80% of participants in the placebo-7 ropinirole (PR) treatment group. The highest incidence of AEs (≥20% in any treatment group) 8 was related to nervous-system disorders (40% in the PR group and 58·3% in the RR group), 9

infections and infestations (60% in the PR group and 41·7% in the RR group), and general 10 disorders and administration-site conditions (60% in the PR group and 33·3% in the RR group). 11

Extended ropinirole treatment was associated with a higher frequency of somnolence (40%) and 12 constipation (60%). Pharmacokinetic data are summarized in figure S2 and table S1. 13

During the double-blind period, the mean ALSFRS-R slope per month before and after treatment 16 was 1·042 (95% CI, 0·249 to 1·835) in the ropinirole group compared with 1·254 (95% CI, 0·165 17 to 2·344) in the placebo group (table S2) . The difference between groups was −0·212 (95% CI, 18 −1·577 to 1·153). The change in the ALSFRS-R score from day 1 to week 24 of the double-blind 19 period was −5·36 (95% CI, −8·09 to −2·64) for the ropinirole group and −6·82 (95% CI, −10·54 20 to −3·10) for the placebo group (table S3) . The between-group difference in the change in 21 ALSFRS-R scores was 1·46 points (95% CI, −3·15 to 6·07) over 24 weeks of treatment ( figure  22 2A). In addition, participants in the ropinirole group had higher daily physical activity, as 23 measured by METs ( figure 2B ). The difference in METs per month between treatment groups at 24

week 24 was 317·5 (95% CI, 66·3 to 568·7) (table S3). There was a persistent increase in 25 between-group differences in the change in ALSFRS-R scores beyond 24 weeks. The change in 26 the ALSFRS-R score during the entire treatment period was −7·64 (95% CI, −10·66 to −4·63) for 27 the RR group and −17·51 (95% CI, −22·46 to −12·56) for the PR group (table S3) . The treatment 28 difference in the change in ALSFRS-R scores was 9·86 points (95% CI, 4·07 to 15·66) over 48 29 weeks, indicating that RR reduced functional decline (figure 2A). The ALSFRS-R score for each 30 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.05.21267266 doi: medRxiv preprint of the 12 items is also shown (figure S3). Furthermore, we applied a composite endpoint that 1 combined multiple clinically relevant functional components, expressed as the mean z-score. The 2 between-group differences in the mean z-score were 11·27 (95% CI, −5·85 to 28·39), 25·04 (95% 3 CI, 4·34 to 45·74), and 15·27 (95% CI, −11·92 to 42·47) at the end of 24, 39, and 50 weeks, 4 respectively (figure 2C). The results of individual components within the composite endpoint are 5 shown in Figures S4-S7 and Tables S4-S7. 6

To examine the relevance of the ALSFRS-R benefit to survival, we used the CAFS 8 measurement, which adjusts the ALSFRS-R score against mortality. The CAFS score favoured 9 ropinirole only in the open-label extension period (difference in median CAFS scores, 6·0; 95% 10 CI, −5 to 9) and the entire treatment period (difference in median CAFS scores, 9·0; 95% CI, 1 to 11 12) but not in the double-blind period (difference of median CAFS scores, 4·0; 95% CI, −6 to 12 10) (figure 3A). Related to respiratory outcome, 14·3% of participants in the placebo group 13 reached ≤ 50%FVC in contrast to 0% in the ropinirole group in the double-blind period (95% CI, 14 −51·3 to 11·4), while 50% of participants in the PR group reached ≤ 50%FVC beyond 40 weeks 15 in contrast to 0% in the RR group (RR group: 7·7%; PR group: 42·9%; difference, −35·2; 95% 16 CI, −67·9 to 2·1) (figure 3B). Notably, %FVC at baseline was not different between the RR and 17 RP groups (95% CI, −4·85 to 30·8). 18

We also investigated the time to death or certain disease progression events. There were 7 out of 19 7 (100%) events in the PR group and 7 out of 13 (54%) events in the RR group, suggesting a 20 twofold decrease in disease progression in the RR group (tables S9, S10A). The RR group had an 21 extended time to the first disease progression event (median event-free survival: 50·3 weeks vs. 22

22·4 weeks in the PR group) (log-rank test: 95% CI, 4·3 to 37·4; Cox regression model analysis: 23 hazard ratio = 0·25, 95% CI, 0·08 to 0·80) (figure 3C). We observed a higher proportion of 24 participants who progressed to grade 4 ALS severity or above in the placebo group at the end of 25 24 weeks (71% for placebo and 53% for ropinirole groups) and 48 weeks (100% for PR and 58% 26 for RR groups) (figure S8, table S9B). Moreover, we identified liquid biomarkers related to the 27 pathomechanism of ALS (figure S9A-C). 28 29 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.05.21267266 doi: medRxiv preprint 4 DISCUSSION 1 In our previous in vitro drug efficacy study using patient-derived iPSC-MNs 5 , the effect of 2 ropinirole on ALS was evident at 0·1, 1, and 10 µmol/L. The estimated ropinirole concentration 3 at 2 mg of Requip CR is approximately 5 nmol/L and that at 16 mg is approximately 50 nmol/L 4 in plasma and CSF. 21 In other experiments, the efficacy of ropinirole was dose-dependent at 5 ropinirole concentrations of 1 nmol/L and 10 µmol/L (figure S10), indicating that 2 mg of 6

Requip CR is effective. However, it is desirable to administer up to 16 mg, which is the 7 maximum approved dosage for use in PD in Japan. 8

Following the administration of 16 mg of ropinirole, the CSF concentration of ropinirole reached 9 approximately 18 nmol/L (table S1) and remained at a steady state. This observation is consistent 10 with the effective concentration of ropinirole in suppressing ALS-related damage in iPSC-11 derived MNs, which ranged from 1 nmol/L or more based on the present (figure S10) and 12 previous results. 5 Steady exposure to 18 nmol/L ropinirole was not associated with any serious 13

AEs that led to trial discontinuation. This trial demonstrated that fixed-dose ropinirole (16 mg) 14 had no specific safety concerns. 15

Overall, the incidence of AEs, most of which had been reported previously, were similar within 16 both groups (table 2A, B). Although gastrointestinal disorders had a high incidence at 76·9% in 17 the ropinirole group (14·3% in the placebo group), these symptoms were temporary mild nausea 18 and diarrhoea, and there were no participants in which the continuation of oral administration 19 was hindered (table 1) . Therefore, ropinirole (2-16 mg) is tolerable for ALS patients. 20

Interestingly, the incidence of ropinirole-induced gastrointestinal disorders in PD patients and 21 healthy individuals in Japan is approximately 5-12% (pharmaceutical interview form for 22

Requip CR tablets, version 6) and 0% (table S10), respectively, which is different from the 23 results in ALS patients in this study. Therefore, gastrointestinal symptoms are not considered to 24 be a major adverse effect of ropinirole, and the reason why many gastrointestinal symptoms 25 appeared in ALS patients in this clinical trial is unknown. Regarding safety concerns, 26 gastrointestinal adverse effects for ALS patients might complicate care because ALS patients 27 have poor BMI, malnutrition, and cachexia; however, the ropinirole group did not differ 28 significantly from the placebo group in weight drop or in the ALSAQ-40 (eating and drinking) 29 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.05.21267266 doi: medRxiv preprint score (figures S6 and S7). Thus, we thought that gastrointestinal symptoms did not significantly 1 affect safety or tolerability in this trial. Because the study was primarily designed to assess safety 2 and tolerability, we chose to present our clinical findings regarding the secondary outcomes as 3 reference for further study. Moreover, regarding the assurance of blinding, the ALSFRS-R score 4 includes both subjective and objective assessments. The investigators did indeed evaluate the 5 patients objectively, assessing at least half of the ALSFRS-R items (i.e., speech, handwriting, 6 cutting food and handling utensils, walking, climbing stairs and respiratory insufficiency). In our 7 posthoc analysis of the transition of each of the 12 items in the ALSFRS-R, no obvious 8 differences were noted between the results of subjective and objective assessment items (figure 9 S3). Therefore, blinding was not broken, and outcomes were not influenced throughout the study. 10

The blinding was kept throughout, and it was plausible that patients and investigators would not 11 know which group had active or placebo treatment; therefore, outcomes were not influenced 12 during the study. 13

The estimated effect size of ropinirole observed for a change in the ALSFRS-R score ranged 14 from 1·46 points to 9·86 points over 48 weeks, equivalent to a 21%-60% slower rate of 15 functional decline. Neurologists generally perceive a treatment difference of >20% as somewhat 16 clinically meaningful. 22 Accordingly, the FDA and PMDA-approved ALS drug edaravone 17 reduced the rate of functional decline by 33% over 24 weeks. 23 Moreover, clinical evaluation 18 items such as the CAFS score, muscle strength, physical activity, pulmonary function, and 19 composite z-score might be useful as evaluation indexes for the efficacy of ropinirole. The CAFS 20 endpoint is advantageous because it evaluates functional and survival outcomes concomitantly 21 without relying on statistical assumptions. CAFS is well adjusted for missing values due to death 22 or drop-outs. 13 However, CAFS measurements may be less relevant because there was only one 23 death in this study, indicating that mortality did not confound the survival analysis per se. 24

Ropinirole, a non-ergot dopamine agonist, was previously approved for the treatment of PD. The 25 full mechanism of action of ropinirole in ALS is not yet understood. Based on our previous 26 reports and according to its structural characteristics, its effects might be dopamine D2 receptor 27 (D2R)-dependent and D2R-independent. 5, 21 With regard to the dopamine D2R-dependent anti-28 ALS mechanism of ropinirole, we confirmed the protein expression of dopamine D2R on 29 anterior horn cells in a healthy human spinal cord and human iPSC-derived LMNs (figures S11 30 and S12), which is consistent with the transcriptome data. 21 Furthermore, D2R couples with Gi 31 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 10 With regard to dopamine D2R-independent mechanisms, it is notable that ropinirole is a 11 lipophilic cation that readily localizes to the mitochondrial inner membrane due to its tertiary 12 amine moiety and possesses antioxidant properties related to its oxindole structure. 21 Consistent 13 with this, urine 8-hydroxy-2'-deoxyguanosine, a surrogate marker of oxidative stress, was not 14 increased in the ropinirole group throughout the entire study period (figure S9A). These findings 15 suggest that ropinirole may scavenge mitochondrial reactive oxygen species and protect cells 16 against mitochondrial damage in ALS. In addition, ropinirole suppressed increases in ALS 17 pathomechanism-related markers, such as serum ferritin 28, 29 and high-sensitivity C-reactive 18 protein, 30 throughout the entire study period (figure S9A). Interestingly, bromocriptine mesylate, 19 an ergot alkaloid and agonist of the same dopamine receptor, namely, D2R, is expected to have 20 an effect on dopamine D2R-independent and neuronal apoptosis inhibitory protein (NAIP), an 21 oxidative stress-induced cell death suppressor -mediated anti-ALS mechanism. 6,31 Collectively, 22 the precise mechanism of action of ropinirole in ALS warrants further investigation. 23

Interpretations of efficacy analyses in this feasibility study were limited by the small sample size 25 of 20 participants. This was further compounded by the unexpectedly higher rate of 26 discontinuation in this study than the historical rate in clinical trials of ALS (~20%) 32 ;46·2% 27 (6/13) of the participants in the ropinirole group and 85·7% (6/7) in the placebo group 28 discontinued the trial (table S11), and the ratio of patients in the ropinirole versus placebo group 29 changed, particularly in the open-label extension period. 30 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ;

These discontinuation rates, particularly during the open-label extension phase, were attributable, 1 at least in part, to the COVID-19 outbreak, which accounted for 23% and 29% of the participants 2 in the ropinirole and placebo groups, respectively. Therefore, it may have had some undesirable 3 influence on the objective interpretation of the results. The number of participants in the placebo 4 group who discontinued the trial due to a worsening condition (47%) was higher than that in the 5 ropinirole group (23%). We did not apply any imputation to the missing data but used the 6 MMRM to infer missing data. In a recent randomized and controlled trial of rasagiline for ALS, 7 60% of the placebo group withdrew from the trial. As a result, the investigators increased the 8 power of the study by utilizing placebo (n=8) and historical placebo controls (n=177). 33 In the 9 future, the addition or adoption of historical placebo controls may be a plausible approach to 10 enrich the placebo cohort, particularly for trials with an extended period. 11

In this trial, the placebo group had more bulbar onset, more female patients and a lower BMI at 13 baseline, which could be the relevant prognostic factors for ALS. 34-36 These are major 14 weaknesses of this trial. In addition, there are some points to be discussed for further study. It is 15 important to note that the slope for the ALSFRS-R decline (−3·4 points) was consistent between 16 the ropinirole and placebo groups during the 12-week run-in period. Additionally, the onset of 17 disease is self-reported and can be influenced by the sensitivity and character of an individual 18 patient; therefore, it is difficult to confirm the accuracy of the period of disease duration. We 19 considered the latest disease progression rate to be more important and emphasized this 20 progression rate with the ALSFRS-R during the 12-week pre-observation period. These 21 observations ruled out potential baseline imbalances related to differences in disease duration. 22

Moreover, previous observational studies showed that the relationship between bulbar onset and 23 survival prognosis were controversial after adjustments for the other clinical features of ALS. 34-24 37 In practice, both the bulbar-onset group and the nonbulbar-onset group showed almost 25 identical transitions in ALSFRS-R scores. In addition, both the ropinirole and placebo groups 26 were divided into the bulbar-onset group and the nonbulbar-onset group (figure S13). When we 27 compared the bulbar-onset and the nonbulbar-onset groups, no significant difference was 28 observed at any time point. Therefore, in this clinical trial, the transition in the ALSFRS-R was 29 not affected by the higher percentage of bulbar-onset patients in the placebo group. 30 31 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.05.21267266 doi: medRxiv preprint Although we observed clinically meaningful differences between the treatment groups for 1 functional and survival outcomes, these differences were primarily observed in the open-label 2 phase. During the double-blind phase, we observed statistically significant treatment differences 3 only for physical activity. Indeed, the rate of decline in the ALSFRS-R score in the placebo 4 group was not improved even during the open-label extension period when the active drug was 5 started. Interestingly, a similar phenomenon was observed in another trial. 38 Although the 6 underlying mechanism of this observation remains unclear, we postulate that taking ropinirole 7 earlier and for longer is necessary to demonstrate its efficacy in participants with ALS. 8 Furthermore, the patient population was skewed towards early-stage ALS (the total ALSFRS-R 9 score at baseline was 39·5±3·0); thus, we also have no conclusive empirical data to demonstrate 10 whether ropinirole was effective in patients with advanced ALS. Taken together, the 11 uncontrolled data with a limited sample size reported in this feasibility study should be 12 interpreted with caution and must be further validated with, ideally, advanced trials and trial 13 designs. Therefore, the efficacy of ropinirole in ALS deserves further investigation in larger, 14 multinational, randomized controlled trials. 39 15 16 Although this trial is a randomized feasibility trial, the results of this trial encourage further study 17 using ropinirole in ALS worldwide. To the best of our knowledge, the ROPALS trial is the 18 representative touchstone of iPSC-based drug repurposing-enabled trials to define the feasibility 19 of iPSC models in predicting clinical outcomes and replacing failure-prone preclinical transgenic 20 mouse models of ALS. 21 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Keiko Nakayama, Tetsuya Niihori, and Yoko Aoki, the Department of Neurology, Tohoku 31 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The authors confirm that the data supporting the findings of this study are available within the 7 article and its supplementary materials. 8 9 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The body-mass index is the weight in kilograms divided by the square of the height in meters.

8 †The difference in disease duration resulted from the dynamic allocation of trial participants using "≥30 months or 9 <30 months after onset" as an adjustment factor because we initially did not expect a statistically significant 10 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.05.21267266 doi: medRxiv preprint variation within the group of participants. However, the group of participants in the <30 months after onset group 1 was diverse. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 2 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.05.21267266 doi: medRxiv preprint *The safety population included all participants who received at least one dose of ropinirole or placebo. The 1 relevance of adverse events or serious adverse events to the intervention was determined by the site investigator.

2 †Adverse events and serious adverse events were classified according to system organ class and preferred terms in 3 the Medical Dictionary for Regulatory Activities, version 23·1. 4 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Trial regimen interrupted owing to adverse eventno. Skin and subcutaneous-tissue disorders 0 (0·0-24·7) 0 (0·0-41·0) 1 (8·3, 0·2-38·5) 0 (0·0-52·2)

Psychiatric disorders 0 (0·0-24·7) 0 (0·0-41·0) 0 (0·0-26·5) 0 (0·0-52·2)

Hepatobiliary disorders 0 (0·0-24·7) 0 (0·0-41·0) 0 (0·0-26·5) 0 (0·0-52·2)

Renal and urinary disorders 0 (0·0-24·7) 0 (0·0-41·0) 0 (0·0-26·5) 0 (0·0-52·2)

Metabolism and nutrition disorders 0 (0·0-24·7) 0 (0·0-41·0) 0 (0·0-26·5) 0 (0·0-52·2)

Cardiac disorders 0 (0·0-24·7) 0 (0·0-41·0) 0 (0·0-26·5) 0 (0·0-52·2) Vascular disorders 0 (0·0-24·7) 0 (0·0-41·0) 0 (0·0-26·5) 0 (0·0-52·2) Blood and lymphatic system disorders 0 (0·0-24·7) 0 (0·0-41·0) 0 (0·0-26·5) 1 (20·0, 0·5-71·6)

Eye disorders 0 (0·0-24·7) 0 (0·0-41·0) 0 (0·0-26·5) 0 (0·0-52·2)

Reproductive system and breast disorders 0 (0·0-24·7) 0 (0·0-41·0) 1 (8·3, 0·2-38·5) 0 (0·0-52·2)

Investigations 0 (0·0-24·7) 1 (14·3, 0·4-57·9) 1 (8·3, 0·2-38·5) 0 (0·0-52·2) 1 4 †Adverse events and serious adverse events were classified according to system organ class and preferred terms in 5 the Medical Dictionary for Regulatory Activities, version 23·1. 6 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. The diagram illustrates the screening, randomization, and follow-up processes in the ROPALS 3 trial. Trial participants who completed the run-in period were randomized to receive either 4 ropinirole or placebo at a 3:1 ratio. Due to dynamic allocation and allocation adjustment factors, 5 13 participants were assigned to receive ropinirole and 7 participants were assigned to receive 6 placebo (approximately a 2:1 ratio). The in vitro evaluations of drug effects and exploration of 7 new biomarkers using patient iPSC-derived motor neurons are ongoing. (n=16), and entire trial period (n=20). Scores range from (1) (worst) to (20) (best). 26 (B) The proportion of participants whose %FVC was reduced to 50% over 48 weeks. 27 (C) The proportion of participants with an occurrence of disease progression events, including 28 death, over 48 weeks. 29 ¶ CAFS ranks patient clinical outcomes based on survival time and change in the ALSFRS-R 30 score. Each patient's outcome is compared with every other patient's outcome, assigned a score, 31 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.05.21267266 doi: medRxiv preprint and the summed scores are ranked. The mean rank score for each treatment group is then 1 calculated. A higher mean CAFS score indicates a better group outcome. 2 Abbreviations: CAFS = Combined Assessment of Function and Survival, %FVC = percent 3 predicted Forced Vital Capacity, ALSFRS-R = Revised ALS Functional Rating Scale. 4

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted December 7, 2021. ; https://doi.org/10.1101/2021.12.05.21267266 doi: medRxiv preprint

Amyotrophic Lateral Sclerosis

Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs

Trends in clinical success rates and therapeutic focus

Towards Advanced iPSC-7 based Drug Development for Neurodegenerative Disease

Modeling sporadic ALS in iPSC-derived motor 10 neurons identifies a potential therapeutic agent

Bromocriptine methylate suppresses glial 12 inflammation and moderates disease progression in a mouse model of amyotrophic lateral 13 sclerosis

Reduction of oxidative stress in amyotrophic lateral 15 sclerosis following pramipexole treatment

Bromocriptine Mesylate Attenuates Amyotrophic 18 Lateral Sclerosis: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Research in 19 Japanese Patients

Dexpramipexole versus placebo for 25 patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind

The ALSFRS-R: a revised ALS functional 28 rating scale that incorporates assessments of respiratory function

The Combined Assessment of Function and Survival 31 (CAFS): A new endpoint for ALS clinical trials

Real-time 34 estimation of daily physical activity intensity by a triaxial accelerometer and a gravity-35 removal classification algorithm

Ropinirole hydrochloride remedy for 37 amyotrophic lateral sclerosis -Protocol for a randomized, double-blind, placebo-controlled, 38 single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial)

41 version) D15a. Mitsubishi Tanabe Pharma Corporation: The second confirmatory study 42

Confirmatory double-blind, parallel-group, placebo-44 controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral 45 sclerosis patients

Accelerometry for remote monitoring of 1 physical activity in amyotrophic lateral sclerosis: a longitudinal cohort study

Stratification of amyotrophic 4 lateral sclerosis patients: a crowdsourcing approach

Issues in outcomes research: an overview of randomization 6 techniques for clinical trials

Clinical 10 significance in the change of decline in ALSFRS-R

Safety and efficacy of edaravone in well-defined patients 13 with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. The 14

Human amyotrophic lateral sclerosis excitability 16 phenotype screen: Target discovery and validation

Modulates Neuronal Network Activity through the Activation of Gα and Gβγ Subunits

A pivotal role of FOS-mediated BECN1/Beclin 1 21 upregulation in dopamine D2 and D3 receptor agonist-induced autophagy activation